Venous Thromboses Clinical Trial
Official title:
Role of Clonal Hematopoiesis and NETs Formation in Unusual Venous Thrombosis (CLODETTE)
Thrombo-embolic venous diseases are represented by deep venous thrombosis and/or pulmonary embolism. In some patients with repeated thrombosis or occurrence of thrombosis in unusual sites, the etiological workup remains negative, which represents a problem for the management of the anticoagulant treatments. Recently, two factors have been identified as important in the physiopathology of hemostasis and coagulation: the presence of clonal hematopoiesis of indetermined potential (CHIP) and the formation of neutrophil extracellular traps (NETs). In this study, these two factors will be studied in patients with repeated venous thrombosis or thrombosis occurring in unusual site.
It has recently been shown that some patients clonal have mutations at a low level in hematopoietic cells (this phenomenon is named clonal hematopoiesis of indetermined potential (CHIP)) and that the presence of a clonal hematopoiesis is associated with an increased cardiovascular risk. However, few data exist about the implication of CHIP in venous thrombosis. Neutrophils extracellular traps are involved in the activation of hemostasis and coagulation. Murine models have highlighted the crucial role of NETs in the physiopathology of venous thrombosis. In patients, studies have demonstrated that NETs markers were present in arteries lesions as coronary plaques. However, few studies have analyzed the NETosis in the setting of venous thrombosis. The study hypothesis is that patients with venous thrombosis may have an increased prevalence of CHIP and/or an increased NETosis formation, which may represent a predisposition for the occurrence of venous thrombosis. We also speculate that patients with CHIP may have an increased NETosis, due to the presence of activating clonal mutations in neutrophils. Patients included will be : younger than 50-years-old with repeated thrombosis or thrombosis of unusual sites (cerebral venous thrombosis, splanchnic thrombosis) with a negative etiological workup and notably the absence of constitutional or acquired venous thrombosis risk factors. In this population, we will analyze the prevalence of CHIP and the NETosis via the study of 4 different NETosis plasmatic markers. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT03613402 -
BRAVO - Betrixaban Registry Using Real Time Observations in Acute Medical Illness to Assess Venous Thrombosis and Bleeding Outcomes
|
||
Recruiting |
NCT05409976 -
The GORE® VIAFORT Vascular Stent IVC Study
|
N/A | |
Completed |
NCT03015025 -
Pharmacogenetic Dosage Algorithm for Acenocoumarol
|
N/A | |
Completed |
NCT03911661 -
Fearon Algorithm in Warfarin Patient Self-Management
|
N/A | |
Recruiting |
NCT05449808 -
Evaluation of Thromboprophylaxis Appropriateness in Hospitalized Medical Patients
|
||
Withdrawn |
NCT05246943 -
The Correlation of a D-dimer Testing Protocol With Venous Thromboembolism in Surgical Colorectal Patients
|
||
Recruiting |
NCT01339611 -
Education Program for Patients Receiving Oral Anticoagulation
|
N/A | |
Completed |
NCT04367831 -
Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19
|
Phase 4 | |
Completed |
NCT04824118 -
Clotting Parameters After Medical Abortion
|
||
Withdrawn |
NCT01810237 -
Validation of a Novel Dabigatran Based Peri-Operative Bridging Anticoagulation Protocol for Patients on Chronic Warfarin Therapy
|
N/A | |
Recruiting |
NCT05489588 -
The GORE® VIAFORT Vascular Stent Iliofemoral Study
|
N/A | |
Completed |
NCT05087108 -
Evaluation of the OsciPulse Rapid Cycling Compression Device Effects on Venous Blood Flow
|
Early Phase 1 | |
Terminated |
NCT04128956 -
Aspirin® Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis in Patients With PTS
|
Phase 2 | |
Completed |
NCT04439383 -
Risk Stratification for Venous Thromboembolism in Hospitalized Medical Patients
|
||
Not yet recruiting |
NCT06452342 -
TRanEXamic Acid to Decrease Heavy Menstrual Bleeding in Individuals Anticoagulated for Venous Thromboembolism Pilot Study
|
Phase 4 | |
Recruiting |
NCT06087952 -
Leiden Thrombosis Recurrence Risk Prevention
|
N/A | |
Completed |
NCT05515120 -
Rivaroxaban Plus Aspirin to Manage Recurrent Venous Thromboembolic Events
|
Phase 2/Phase 3 | |
Completed |
NCT03611894 -
Comparison of the Radiological Pattern Between the Cerebral Stroke of Arterial and Venous Origin
|
||
Completed |
NCT03835780 -
The Risk of Venous Thromboembolism in Systemic Inflammatory Disorders: a United Kingdom (UK) Matched Cohort Study
|
||
Recruiting |
NCT05729464 -
Risk Factors and Prediction Model of Cancer-associated Venous Thromboembolism
|